Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Central Nervous System Neoplasms 1

Interventions

Temozolomide 44Radiotherapy 16Bevacizumab 9Surgical Procedures, Operative 5Carmustine 5Lomustine 4Drug Therapy 4pembrolizumab 3Sunitinib 3Standard of Care 3Radiation 3Procarbazine 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3Chlorotoxin 3Carboplatin 3Blood Specimen Collection 3tislelizumab 2fludarabine 2camrelizumab 2Radiosurgery 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Hyperbaric Oxygenation 2Ethanol 2Cyclophosphamide 2Chemotherapy, Adjuvant 2CT-322 2Bortezomib 2Aminolevulinic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Glioblastoma × CT-322 × Clear all
NCT00562419 2010-10-27

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 2 Unknown
72 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

NCT00768911 2010-10-27

CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme

Adnexus, A Bristol-Myers Squibb R&D Company

Phase 1 Unknown
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡